SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/58899"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/58899" > High-grade astrocyt...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005818naa a2200853 4500
001oai:gup.ub.gu.se/58899
003SwePub
008240910s2006 | |||||||||||000 ||eng|
009oai:DiVA.org:umu-13651
009oai:DiVA.org:uu-25116
009oai:DiVA.org:liu-37621
0247 a https://gup.ub.gu.se/publication/588992 URI
0247 a https://doi.org/10.1007/s11060-005-9106-92 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-136512 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-251162 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-376212 URI
040 a (SwePub)gud (SwePub)umud (SwePub)uud (SwePub)liu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Henriksson, Rogeru Umeå universitet,Onkologi4 aut0 (Swepub:umu)rohe0003
2451 0a High-grade astrocytoma treated concomitantly with estramustine and radiotherapy.
264 c 2006-04-06
264 1b Springer Science and Business Media LLC,c 2006
520 a Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma. The present study is an open randomized clinical trial comparing estramustine phosphate (Estracyt) in addition to radiotherapy with radiotherapy alone as first line treatment of astrocytoma grade III and IV. The 140 patients included were in a good clinical condition with a median age of 55 years (range 22-87). Estramustine was given orally, 280 mg twice daily, as soon as the diagnosis was established, during and after the radiotherapy for a period of in total 3 months. Radiotherapy was delivered on weekdays 2 Gy daily up to 56 Gy. Eighteen patients were excluded due to misclassification, leaving 122 patients eligible for evaluation. Overall the treatment was well tolerated. Mild or moderate nausea was the most common side effect of estramustine. The minimum follow-up time was 5.2 years for the surviving patients. For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group. In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively. Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively. In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively. Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups. No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol. In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy, however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Adult
653 a Aged
653 a Aged
653 a 80 and over
653 a Antineoplastic Agents
653 a Alkylating
653 a administration & dosage
653 a Astrocytoma
653 a drug therapy
653 a radiotherapy
653 a Brain Neoplasms
653 a drug therapy
653 a radiotherapy
653 a Combined Modality Therapy
653 a Estramustine
653 a administration & dosage
653 a Female
653 a Humans
653 a Male
653 a Middle Aged
653 a Quality of Life
653 a Radiotherapy Dosage
653 a Severity of Illness Index
653 a Survival Analysis
653 a Treatment Outcome
653 a Astrocytoma
653 a MEDICINE
7001 a Malmström, Annika,d 1957-u Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Onkologiska kliniken US4 aut0 (Swepub:liu)annma14
7001 a Bergström, Peru Umeå universitet,Onkologi4 aut0 (Swepub:umu)pebe0049
7001 a Berg, Gertrud,d 1944u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences4 aut0 (Swepub:gu)xbeger
7001 a Trojanowski, Thomas4 aut
7001 a Andreasson, Lars4 aut
7001 a Blomquist, Eriku Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi4 aut0 (Swepub:uu)erikblom
7001 a Jonsborg, Sonny4 aut
7001 a Edekling, Tomas4 aut
7001 a Salander, Pär,d 1948-u Umeå universitet,Institutionen för socialt arbete,Onkologi4 aut0 (Swepub:umu)pasa0001
7001 a Brännström, Thomasu Umeå universitet,Patologi4 aut0 (Swepub:umu)thbr0001
7001 a Bergenheim, A Tommyu Umeå universitet,Farmakologi4 aut0 (Swepub:umu)tobe0004
7102 a Umeå universitetb Onkologi4 org
7730 t Journal of neuro-oncologyd : Springer Science and Business Media LLCg 78:3, s. 321-6q 78:3<321-6x 0167-594Xx 1573-7373
8564 u http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16598426&dopt=Citation
8564 8u https://gup.ub.gu.se/publication/58899
8564 8u https://doi.org/10.1007/s11060-005-9106-9
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-13651
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-25116
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-37621

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy